SLNOのチャート
SLNOの企業情報
| symbol | SLNO |
|---|---|
| 会社名 | Soleno Therapeutics Inc （カプニア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ソレノ・セラピーティクス(Soleno Therapeutics Inc.)（旧名:Capnia Inc.）は新生児のデバイスと診断を開発・商品化する米国の医療機関である。また、ガスフローの精密計量のための独自の技術に基づく治療プラットフォームを備える。同社はCoSense呼吸終期一酸化炭素（ETCO）モニター、NeoPIP幼児蘇生器及びアクセサリ、並びにSerenz Nasal Reliefなどの製品を提供する。同社は危険な溶血速度を検出するために、ETCOを測定するCoSense終末呼気一酸化炭素モニターを開発した。NeoPIP幼児蘇生装置ユニット及び付属品を含む幼児ソリューション製品ラインは臨床環境における新生児・幼児の蘇生の制御された精確な蘇生のために設計される。Serenz Nasal Reliefは、鼻腔を洗浄するために二酸化炭素（CO2）ガスを使用する手持ちの鼻洗浄器である。 カプニアは、米国の医療機器メ―カ―。ガスフロ―の定量性に対する独自技術に基づいた診断治療の開発と商品化に取り組む。主力製品は、鎌形赤血球病検査器の｢CoSense｣や、アレルギ―性鼻炎の治療薬の｢Serenz｣。本社は、カリフォルニア州レッドウッドシティ。 Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program. |
| 本社所在地 | 1235 Radio Road Suite 110 Redwood City CA 94065 USA |
| 代表者氏名 | Anish Bhatnagar アニッシュ・バトナガル |
| 代表者役職名 | President Chief Executive Officer Interim Principal Financial and Accounting Officer Director |
| 電話番号 | +1 650-213-8444 |
| 設立年月日 | 36373 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | 18人 |
| url | www.capnia.com |
| nasdaq_url | https://www.nasdaq.com/symbol/slno |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -9.89886 |
| 終値（lastsale） | 1.96 |
| 時価総額（marketcap） | 41971179.32 |
| 時価総額 | 時価総額（百万ドル） 40.25807 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 27.66507 |
| 当期純利益 | 当期純利益（百万ドル） -6.87382 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Soleno Therapeutics Inc revenues decreased from $3K to $0K. Net loss before extraordinary items increased 97% to $10.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Change in fair value of warrants liabili increase from $160K to $3.6M (expense) Research and development increase from $1.3M to $2.9M (expense). |
SLNOのテクニカル分析
SLNOのニュース
Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days 2023/03/28 12:00:00 GlobeNewswire
REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time.
Soleno Therapeutics GAAP EPS of -$0.58 beats by $0.22 2023/03/21 20:49:56 Seeking Alpha
Soleno Therapeutics press release (SLNO): Q4 GAAP EPS of -$0.58 beats by $0.22.As of December 31, 2022, Soleno had cash and cash equivalents of approximately $14.6 million.
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results 2023/03/21 20:05:00 GlobeNewswire
REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2022.
Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference 2023/03/07 13:00:00 GlobeNewswire
REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 11:20 AM Eastern Time.
7 Top Short-Squeeze Candidates to Watch in February 2023/02/01 21:25:01 InvestorPlace
While everyone knows that in order to have a market, there must be bulls and bears, that’s not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position. At some point, though, those borrowed shares must be returned. For the bears, they can be returned either at a profit or a loss. Now, in order to panic the bears into buying back their borrowed shares before they rise too much, contrarian bulls can deliberately bid up negatively targeted securities. Therefore, the top short-squeeze candidates offer an incredibly lucrative opportunity to make big money quickly. Still, it’s important to remember the cardinal rule about this contrarian practice: flawed companies usually attract heavy short interest. As a bull, even if you make money on your trade, you probably don’t want to hang around too long. Otherwise, your fellow bulls might dump shares on you.
SLNO stock drops as reverse stock split takes effect (NASDAQ:SLNO) 2022/08/26 11:17:47 Seeking Alpha
Clinical-stage biotech Soleno Therapeutics, Inc. (SLNO) dropped ~13% in the pre-market trading Friday as the company shares began trading on a split-adjusted basis following a…
Eye-popping stocks: Soleno Therapeutics, Inc. (NASDAQ:SLNO 0.25%), Borqs Technologies, Inc. (NASDAQ:BRQS 1.68%) 2022/08/26 01:34:11 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Eye-popping stocks: Soleno Therapeutics, Inc. (NASDAQ:SLNO 0.25%), Borqs Technologies, Inc. (NASDAQ:BRQS 1.68%) appeared first on Stocks Equity .
Analysts Release Price Targets And Ratings For Soleno Therapeutics Inc. (SLNO) 2022/08/12 15:30:00 Stocks Register
Soleno Therapeutics Inc. (NASDAQ:SLNO) concluded the trading at $0.19 on Thursday, August 11 with a rise of 9.55% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.18 and 5Y monthly beta was reading 0.28 with its price kept floating in the … Analysts Release Price Targets And Ratings For Soleno Therapeutics Inc. (SLNO) Read More »
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results 2022/08/10 20:05:00 GlobeNewswire
REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2022.
Enthralling stocks: First Wave BioPharma, Inc. (NASDAQ:FWBI -0.32%), Soleno Therapeutics, Inc. (NASDAQ:SLNO 3.27%) 2022/08/08 00:19:27 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enthralling stocks: First Wave BioPharma, Inc. (NASDAQ:FWBI -0.32%), Soleno Therapeutics, Inc. (NASDAQ:SLNO 3.27%) appeared first on Stocks Equity .
Soleno Therapeutics Inc. (NASDAQ: SLNO) Surged -46.71% In 6 Months – Here’s What Happens Next 2022/07/30 16:00:00 Marketing Sentinel
Soleno Therapeutics Inc. (NASDAQ:SLNO)’s traded shares stood at 0.82 million during the last session, with the company’s beta value hitting 0.29. At the close of trading, the stock’s price was $0.17, to imply a decrease of -5.00% or -$0.01 in intraday trading. The SLNO share’s 52-week high remains $1.04, putting it -511.76% down since that … Soleno Therapeutics Inc. (NASDAQ: SLNO) Surged -46.71% In 6 Months – Here’s What Happens Next Read More »
Soleno Therapeutics Inc. (NASDAQ: SLNO) Could Pass $7.00 In One Year Stock Forecast 2022/07/26 12:00:00 Stocks Register
Soleno Therapeutics Inc. (NASDAQ:SLNO) price closed lower on Monday, July 25, dropping -1.26% below its previous close. A look at the daily price movement shows that the last close reads $0.17, with intraday deals fluctuated between $0.1717 and $0.18. The company’s 5Y monthly beta was ticking 0.38. Taking into account the 52-week price action we … Soleno Therapeutics Inc. (NASDAQ: SLNO) Could Pass $7.00 In One Year Stock Forecast Read More »
Deliciously stocks You Should follow: Soleno Therapeutics, Inc. (NASDAQ:SLNO -6.72%), DURECT Corporation (NASDAQ:DRRX -3.49%) 2022/07/25 00:52:01 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Deliciously stocks You Should follow: Soleno Therapeutics, Inc. (NASDAQ:SLNO -6.72%), DURECT Corporation (NASDAQ:DRRX -3.49%) appeared first on Stocks Equity .
Soleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful 2022/07/20 14:59:56 Benzinga
Soleno Therapeutics Inc (NASDAQ: SLNO ) provided an update following recent communications with the FDA regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for Prader-Willi syndrome (PWS). The FDA acknowledged that data from a proposed randomized withdrawal phase of Study C602 would have the potential to address its … Full story available on Benzinga.com
Why Shares Of Soleno Therapeutics Are Trading Higher 2022/07/20 14:38:35 Benzinga
Shares of small-cap penny stock Soleno Therapeutics, Inc. (NASDAQ: SLNO ) shares are trading higher after the company provided a regulatory update following recent communications with the FDA regarding the development of DCCR for the treatment of Prader-Willi syndrome. Earlier this year, Soleno submitted a proposal to add a randomized withdrawal period to Study C602 in order to obtain additional controlled data … Full story available on Benzinga.com